Capricor Therapeutics

About:

Capricor Therapeutics is a biotechnology company focusing on cell and exosome-based therapeutics.

Top Investors: National Institutes of Health, U.S. Department of Defense, Cedars Sinai, Broadview Ventures, California Institute for Regenerative Medicine

Description:

Capricor Therapeutics is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of cell and exosome-based therapeutics for the treatment and prevention of diseases. Its CAP-1002 is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and COVID-19. The company was founded in 2005 and is headquartered in Los Angeles, California.

Total Funding Amount:

$180M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Los Angeles, California, United States

Founded Date:

2005-01-01

Contact Email:

info(AT)capricor.com

Founders:

Linda Marban

Number of Employees:

11-50

Last Funding Date:

2024-10-17

IPO Status:

Public

Industries: